Great News! Kangrong Pharmaceutical’s Tigecycline for Injection Approved

Beijing Rongying Pharmaceutical Technology Co., Ltd. has received the Drug Registration Certificate for Tigecycline for Injection issued by the relevant regulatory authority, with the drug approval number NMPA Approval No. H20265029. Rongying Pharmaceutical is the R&D subsidiary of Kangrong Pharmaceutical.

Tigecycline for Injection, available in a 50 mg strength, is indicated for the treatment of patients aged 18 years and older with complicated intra-abdominal infections caused by susceptible bacteria, including Citrobacter freundii, Escherichia coli, and Bacteroides fragilis; complicated skin and soft tissue infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA); and community-acquired bacterial pneumonia.